PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest

Part of paid clinical trials in San Francisco, California.

Sponsor
University of California, San Francisco
Study ID
NCT06401707
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Heart Arrest
  • Seizures
  • Status Epilepticus

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Perampanel — DRUG
    Perampanel is a non-competitive AMPA glutamate receptor antagonist.
  • Placebo — DRUG
    Placebo

Study Details

Brain injury is the main cause of death and disability for patients surviving cardiac arrest resuscitation and seizures are diagnosed in up to a third of these patients. The investigators are proposing a pilot randomized placebo-controlled clinical trial to evaluate the safety and feasibility of perampanel use for post-cardiac arrest status epilepticus (PCARSE) prevention after cardiac arrest.

Key Dates

Start date
May 20, 2024
Status verified
Jul 2025
Primary completion
May 20, 2026
Completion
Oct 20, 2026

Study Design

Enrollment
52 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Active Comparator: Perampanel
    Perampanel oral load of 24mg upon randomization followed by 8mg oral dose daily for four more days (second dose one day after load and total treatment duration is 5 days)
  • Placebo Comparator: Placebo
    Placebo oral load upon randomization followed by daily placebo oral dose administration for four more days (second dose one day after load and total placebo administration duration is 5 days)

Primary Outcome Measure

Safety and tolerability of perampanel [ Time Frame: 7 days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Zuckerberg San Francisco General HospitalSan FranciscoCalifornia94110
Edilberto Amorim, MD

Find similar trials in San Francisco, CA

By research site
Zuckerberg San Francisco General Hospital· San Francisco, CA

Related Studies